Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $12 price target.
June 13, 2024 | 9:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on G1 Therapeutics and maintained a $12 price target.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100